TY - JOUR
T1 - Resistance to pyrazinamide in Russian Mycobacterium tuberculosis isolates
T2 - PncA sequencing versus Bactec MGIT 960
AU - Maslov, Dmitry A.
AU - Zaîchikova, Marina V.
AU - Chernousova, Larisa N.
AU - Shur, Kirill V.
AU - Bekker, Olga B.
AU - Smirnova, Tatiana G.
AU - Larionova, Elena E.
AU - Andreevskaya, Sofya N.
AU - Zhang, Ying
AU - Danilenko, Valery N.
N1 - Publisher Copyright:
© 2015 Elsevier Ltd.
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Summary Resistance to pyrazinamide (PZA) may impact clinical outcome of anti-tuberculosis chemotherapy. PZA susceptibility testing using MGIT 960 is not reliable and little information is available on the prevalence of PZA resistance in Russia. A collection of 64 clinical isolates of Mycobacterium tuberculosis, including 35 multidrug resistant and extensively drug-resistant (MDR/XDR), was analyzed for PZA resistance using MGIT 960, Wayne test, and sequencing of PZA resistance genes pncA, rpsA and panD. In addition, we analyzed 519 MDR-TB strains for susceptibility to PZA by MGIT 960. Sequencing of pncA revealed 17 of 25 (68%) MDR strains and all 10 XDR strains harboring pncA mutations. A correlation of φ = 0.81 between MGIT 960 and pncA sequencing was observed. Mutations in rpsA and panD not associated with PZA resistance as defined by MGIT 960 were identified. We found 1 PZA-resistant strain without mutations in known PZA resistance genes. Almost 73% of MDR-TB strains isolated in Moscow, Russia, were PZA-resistant by MGIT 960 testing of 519 MDR-TB clinical isolates. Further studies are needed to determine the role of rpsA and panD mutations in possible low-level PZA resistance and to identify the molecular basis of new PZA resistance in the isolate without known PZA resistance mutations.
AB - Summary Resistance to pyrazinamide (PZA) may impact clinical outcome of anti-tuberculosis chemotherapy. PZA susceptibility testing using MGIT 960 is not reliable and little information is available on the prevalence of PZA resistance in Russia. A collection of 64 clinical isolates of Mycobacterium tuberculosis, including 35 multidrug resistant and extensively drug-resistant (MDR/XDR), was analyzed for PZA resistance using MGIT 960, Wayne test, and sequencing of PZA resistance genes pncA, rpsA and panD. In addition, we analyzed 519 MDR-TB strains for susceptibility to PZA by MGIT 960. Sequencing of pncA revealed 17 of 25 (68%) MDR strains and all 10 XDR strains harboring pncA mutations. A correlation of φ = 0.81 between MGIT 960 and pncA sequencing was observed. Mutations in rpsA and panD not associated with PZA resistance as defined by MGIT 960 were identified. We found 1 PZA-resistant strain without mutations in known PZA resistance genes. Almost 73% of MDR-TB strains isolated in Moscow, Russia, were PZA-resistant by MGIT 960 testing of 519 MDR-TB clinical isolates. Further studies are needed to determine the role of rpsA and panD mutations in possible low-level PZA resistance and to identify the molecular basis of new PZA resistance in the isolate without known PZA resistance mutations.
KW - Drug susceptibility testing
KW - MGIT960
KW - Pyrazinamide
KW - Resistance
KW - Tuberculosis
KW - pncA
UR - http://www.scopus.com/inward/record.url?scp=84940460611&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940460611&partnerID=8YFLogxK
U2 - 10.1016/j.tube.2015.05.013
DO - 10.1016/j.tube.2015.05.013
M3 - Article
C2 - 26071666
AN - SCOPUS:84940460611
SN - 1472-9792
VL - 95
SP - 608
EP - 612
JO - Tuberculosis
JF - Tuberculosis
IS - 5
ER -